Vetnews | Februarie 2026 24 « BACK TO CONTENTS FMD vaccination prevents disease through the elicitation of a strong neutralising antibody response in cattle. We observed that, following inoculation with the highest doses of A24-P2/P3Deopt, cattle in the 107 pfu dose group developed neutralising antibody titers at about the same rate as those animals administered the WT virus, with both groups reaching the protective threshold of 1.2 for cattle by 4 dpi (Fig 3A). Meanwhile, those animals administered 106 pfu of A24-P2/ P3Deopt developed neutralising antibody titers more slowly, reaching a protective threshold by 7 dpi and reaching a maximal titer somewhat lower than the other two treatment groups. A two-way ANOVA mixed effects model revealed highly significant effects for treatment group (P<0.0001), time point (P=0.0001) and treatment group x time point interaction (P<0.0001). Post-hoc comparisons by timepoint revealed significant differences between WT and 106 pfu administered cattle at 7DPI (P=0.0225), 14 (P=0.0009) and 21 dpi (P=0.0068). A statistically significant difference was also detected between WT and 107 pfu administered cattle at 14 dpi (P=0.0359). Additionally, significant differences were detected between 106 and 107 pfu inoculated cattle, at 7 (P=0.0192), 14 (P= 0.0213) and 21 dpi (P=0.0025). To determine the DIVA compliance of this vaccine, we next tested the sera at 0 and 21 dpi for antibodies against FMDV nonstructural (NS) proteins 3B2 and 3Dpol (PrioCheck®ELISA, Applied Biosystems), which had been mutated to serve as a DIVA marker in A24-P2/P3Deopt as in Uddowla et al (2012) 26. We found that while 106 pfu A24-P2/P3Deoptadministered animals remained free of any such antibodies, one animal from our maximum safety dose, 107 pfu dose group, developed these antibodies, leaving the DIVA status of this vaccine in doubt (Fig 3B). Prior to inoculation, however, the virus was sequenced, and the presence of the DIVA marker previously described 26 was confirmed. Our safety assessment of the FMDV A24-P2/P3Deopt strain reveals a virus that is safely administered even via IDL at high doses in cattle without risk of development of clinical disease, though its DIVA compliance needs further investigation. Efficacy Study Having confirmed the safety of FMDV A24-P2/P3Deopt at high doses in cattle, we then moved on to assessing the effective dose range for preventing clinical disease upon homologous challenge. For this efficacy study, we utilised four groups of four Holstein heifers each and subcutaneously (SQ) administered FMDV A24-P2/P3Deopt as either a single dose (105 pfu) or a two-dose series administered at 0 and 14 dpi (104, 105 and 106 pfu). A fifth group of 4 heifers was subcutaneously administered PBS at 0 dpi (Fig 4A). Animals in groups 1 through 4 were sampled daily through 7 dpi for blood and nasal secretions, then weekly thereafter for blood. Animals in group 5 were sampled weekly to check for the absence of virus prior to challenge. At 28 dpi, all animals were challenged with 2.36x104 pfu (equivalent to 104 BID50) of homologous FMDV A24Cruzeiro WT via the IDL route. Following challenge, cattle were clinically examined daily and again sampled daily for blood and nasal secretion up to 7 dpc, then weekly thereafter for blood. To corroborate results obtained during safety studies, cattle were assessed for signs of clinical disease following primary SQ inoculation with FMDV A24-P2/P3Deopt. As expected, they were found to remain free of fever, lymphopenia and the development of FMD vesicles (data not shown). Similar to the IDLinoculated safety dose groups, shedding was absent via both virus isolation as well as RT-qPCR following inoculation (Fig 4B). Additionally, viremia was absent by virus isolation, while variable amounts of circulating viral RNA (102-107 GCP/ml) were detectable—generally only for one day per animal—by RTqPCR from timepoints ranging from 1-4 dpc. Following challenge at 28 dpi, all animals in the control group developed clinical FMD with elevated temperatures starting at 2 dpc and with maximum disease scores by 3 dpc (Fig 5). On the contrary, all animals in the two-dose inoculation groups were found to be protected from the development of clinical FMD (Fig 5). One heifer in the 105 pfu single dose A24-P2/P3Deopt vaccinated group exhibited delayed fever (3-4 dpc) with a peak clinical score reached at 5 dpc, while the other 3 animals in this group were protected from disease after parental challenge. When cattle were assessed for viremia and shedding following challenge, a trend was observed in the inverse relationship between the dose (PFU) of vaccine received and the likelihood and amount of virus detected in both the blood and nasal secretions. (Fig 6). Animals in the control group exhibited viremia and nasal shedding detected by both virus isolation and RT-qPCR starting as early as 1 day after challenge. Viremia peaked at titers of about 104-105 pfu/ml by virus isolation and 108 GCP/ml by RTqPCR, while shedding peaked at 105-107 pfu/ml by virus isolation and 107-1010 GCP/ml by RT-qPCR. By contrast, none of the cattle inoculated with two doses of A24-P2/P3Deopt prior to challenge showed any viremia or RNemia. In parallel, shedding was observed in only 1 out of 4 heifers by RT-qPCR at concentrations of about 104 GCP/ ml among the two groups vaccinated with the highest A24P2/P3Deopt doses (two doses of 105 or 106 pfu). Amongst the two-dose 104 pfu efficacy group, 4/4 heifers displayed shedding by RT-qPCR, with 1/4 also positive for shedding by virus isolation. Finally, among the singledose 105 pfu dose group, the same animal that showed clinical FMD development also became viremic by 1 dpc by both RT-qPCR as well as virus isolation. Similarly, this animal began to shed by 2 dpc when assessed via virus isolation and RT-qPCR. All other heifers in this dose group were only positive for shedding by RT-qPCR and were negative for viremia. Having established that a two-dose prime-boost vaccination strategy with FMDV A24-P2/P3Deopt can prevent clinical FMD at doses ranging from 104-106 when administered SQ, we next assessed the development of neutralising antibody titers. We found that while all dose groups achieved a protective titer—as defined by a log10 serum dilution of ≥1.2 determined experimentally in our lab for other vaccine candidates 27—on average by 7 dpi, the 106 pfu dose group achieved that titer by 4 dpi (Fig 7A). All vaccine dose groups maintained a protective titer leading up to challenge, at which point their serum neutralising antibody titers increased again due to the boost effect of the challenge. A two-way ANOVA mixed effects model revealed significant effects for treatment (P<0.0001), timepoint (P=0.0016), and the interaction effect (P=0.0047) between the two were all significant. Pre-challenge statistical comparisons against the vaccinated groups were not assessed for controls, as blood samples were not collected from control cattle between 4 and 21 dpi. during the pre-challenge period. At 4 dpi, the neutralising antibody titer of animals in the two-dose 106 pfu treatment group was significantly higher than those from the single 105 pfu dose and the two-dose 104 pfu (Ps<0.0001 for both) treatment groups. At 0 dpc, the neutralising antibody titer of the cattle in the twodose 106 pfu treatment group (P=0.0135), along with those in the twodose 105 pfu treatment group (P=0.0023), was found to be significantly higher than that of the control animals, whose titer remained at 0. At 4 dpc neutralizing antibody titer of the cattle in the two dose 105 pfu treatment group (P=0.0156) along with those in the one-dose 105 pfu treatment group (P=0.0065) were found to be significantly higher than the control animals, and at 10 dpc, neutralizing antibody titers of the cattle from the two dose 104 pfu treatment group were found to be significantly higher (P=0.027) than that of the control group. As with the safety study, we again looked to assay for the presence of anti-NSP antibodies in vaccinated cattle to determine the DIVA compliance of this LAV candidate (Fig 7B). Article Live-attenuated foot-and-mouth disease virus vaccine engineered.... <<< 23
RkJQdWJsaXNoZXIy OTc5MDU=